Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.67 +1.20%

+$0.15 today

Market cap
$336.08M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.18M

Average 0.09M

LYEL EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Lyell Immunopharma, Inc.NASDAQ: LYEL

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$1.1, compared with -$0.18 a year earlier. Trailing-twelve-month EPS (Basic) was -$16.98.

Context

  • EPS (Basic) grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 4 analysts of -$6.8 (+57.6%) for the fiscal year ending Dec 2026, a step up from the -1126.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.1+89.9% QoQ
Last fiscal yearDec 2025
-$16.06-1126.0% YoY
LTMMar 2026
-$16.98-1259.1% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-511.1%+34.3%+545.4 pp
1 year-1126.0%+57.6%+1183.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(16.06) USD
Year-over-year change
-1126.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -1259.1% is the lowest of 10, against a peer median of +23.3%.
LYEL Competitors
EPS (Basic) for LYEL and competitors
Company Period LTM YoY 3-year CAGR
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$0.46 USD+52.9%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 0.66 CHF-32.0%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$0.77 USD+37.4%—
GNLXGenelux CorporationLTM Mar 2026-$0.88 USD+1.1%—
EDITEditas Medicine, Inc.LTM Mar 2026-$1.23 USD+59.6%—
AMRNAmarin Corporation plcLTM Mar 2026-$1.62 USD+62.1%—
CABACabaletta Bio, Inc.LTM Mar 2026-$1.97 USD+23.3%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$2.1 USD-40.9%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$3.28 USD+2.7%—
SLNSilence Therapeutics plcLTM Mar 2026-$4.32 USD——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$16.98 USD-1259.1%—
Peer median (excluding LYEL) —+23.3%—

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.